Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • eiretekk eiretekk Nov 19, 2012 3:53 PM Flag

    Lame hit pieces

    You've got to wonder about the origin of today's Forbes article. It builds on a previous hit piece claiming prescription omega 3's are not proven to help cardiac outcomes. These pieces do not deny the non-scientific nature of the so-called studies they're quoting but neither do they expose them. It seems to me the net effect of these hits will be to lower the pps in the short term.
    It seems to me the outcome of the NCE decision is being made moot by the patent portfolio Amarin is building and that another line of attack is therefore needed to hold the pps at these levels. We all know why but the real question is the motive here is who is pulling the strings.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They probably know the NCE decision already and want the price to be lower. This is the old fashion market thieves and crooked for ya. If you notice whenever the price about to move there is a hit piece come out to stabilized the price or lower it. We the retailer share holder will be the last to know any info.

      Lets wait a few days or wks to see the actual reason for all this basher article coming out, usually the new will be good.

      Sentiment: Strong Buy

    • I'm convinced that BP is working Amarin over any way it can to get Vascepa for a song.

      Sentiment: Strong Buy

 
AMRN
1.67-0.13(-7.22%)1:12 PMEDT